Volume 270,
Number 43,
Issue of October 27, 1995 pp. 25949-25955
©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Mycotrienins
A NEW CLASS OF POTENT INHIBITORS OF OSTEOCLASTIC BONE RESORPTION
(Received for publication, July 20, 1995)
Dominik
Feuerbach ,
Rudolf
Waelchli,
Theo
Fehr
,
Jean H. M.
Feyen
Pharmacological intervention using selective tyrosine kinase
inhibitors has been shown to be an effective approach to inhibit
osteoclast function. Here, we report on the structure-activity
relations of benzoquinone ansamycins isolated from Streptomyces
rishirensis, which form a new class of potent inhibitors of
osteoclast-mediated bone resorption. Parathyroid hormone-stimulated
bone resorption was inhibited concentration dependently by both
mycotrienin I and mycotrienin II, showing half-maximal inhibition in
the low nanomolar range in fetal rat long bones in vitro.
Structure-activity relation studies indicate that position 19 contained
within the quinone/hydroquinone element and the double bonds in
position 4, 6, and 8 are crucial for full bioactivity. In contrast,
substitutions in position 22 are well tolerated. The lack of a similar
effect of 2,6-dimethyl-p-benzoquinone and vitamin K signifies
that the mechanism of action is not solely due to the oxygen scavenger
capacity of the quinone/hydroquinone moiety. The inhibition of
osteoclastic bone resorption is in line with the diminished activity of
immunopurified pp60
from bone suggesting that
pp60
is a possible target of mycotrienins in
the organ culture. Thus, mycotrienins may be useful as pharmacologic
inhibitors of osteoclastic bone resorption.